Cargando…

How to Differentiate Benign from Malignant Adrenocortical Tumors?

SIMPLE SUMMARY: Adrenocortical carcinoma is a rare cancer with a poor prognosis. Adrenal tumors are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance to determine the appropriate treatment and follow-up strategy. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Viëtor, Charlotte L., Creemers, Sara G., van Kemenade, Folkert J., van Ginhoven, Tessa M., Hofland, Leo J., Feelders, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431066/
https://www.ncbi.nlm.nih.gov/pubmed/34503194
http://dx.doi.org/10.3390/cancers13174383
_version_ 1783750849947762688
author Viëtor, Charlotte L.
Creemers, Sara G.
van Kemenade, Folkert J.
van Ginhoven, Tessa M.
Hofland, Leo J.
Feelders, Richard A.
author_facet Viëtor, Charlotte L.
Creemers, Sara G.
van Kemenade, Folkert J.
van Ginhoven, Tessa M.
Hofland, Leo J.
Feelders, Richard A.
author_sort Viëtor, Charlotte L.
collection PubMed
description SIMPLE SUMMARY: Adrenocortical carcinoma is a rare cancer with a poor prognosis. Adrenal tumors are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance to determine the appropriate treatment and follow-up strategy. This review summarizes the current diagnostic strategies and challenges to distinguish benign from malignant adrenal lesions. We will focus both on radiological and biochemical assessments, enabling diagnosis of the adrenal lesion preoperatively, and on histopathological and a wide variety of molecular assessments that can be done after surgical removal of the adrenal lesion. Furthermore, new non-invasive strategies such as liquid biopsies, in which blood samples are used to study circulating tumor cells, tumor DNA and microRNA, will be addressed in this review. ABSTRACT: Adrenocortical carcinoma (ACC) is a rare cancer with a poor prognosis. Adrenal incidentalomas are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance considering the large differences in clinical behavior requiring different strategies. Diagnosis of ACC starts with a thorough physical examination, biochemical evaluation, and imaging. Computed tomography is the first-level imaging modality in adrenal tumors, with tumor size and Hounsfield units being important features for determining malignancy. New developments include the use of urine metabolomics, also enabling discrimination of ACC from adenomas preoperatively. Postoperatively, the Weiss score is used for diagnosis of ACC, consisting of nine histopathological criteria. Due to known limitations as interobserver variability and lack of accuracy in borderline cases, much effort has been put into new tools to diagnose ACC. Novel developments vary from immunohistochemical markers and pathological scores, to markers at the level of DNA, methylome, chromosome, or microRNA. Molecular studies have provided insights into the most promising and most frequent alterations in ACC. The use of liquid biopsies for diagnosis of ACC is studied, although in a small number of patients, requiring further investigation. In this review, current diagnostic modalities and challenges in ACC will be addressed.
format Online
Article
Text
id pubmed-8431066
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84310662021-09-11 How to Differentiate Benign from Malignant Adrenocortical Tumors? Viëtor, Charlotte L. Creemers, Sara G. van Kemenade, Folkert J. van Ginhoven, Tessa M. Hofland, Leo J. Feelders, Richard A. Cancers (Basel) Review SIMPLE SUMMARY: Adrenocortical carcinoma is a rare cancer with a poor prognosis. Adrenal tumors are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance to determine the appropriate treatment and follow-up strategy. This review summarizes the current diagnostic strategies and challenges to distinguish benign from malignant adrenal lesions. We will focus both on radiological and biochemical assessments, enabling diagnosis of the adrenal lesion preoperatively, and on histopathological and a wide variety of molecular assessments that can be done after surgical removal of the adrenal lesion. Furthermore, new non-invasive strategies such as liquid biopsies, in which blood samples are used to study circulating tumor cells, tumor DNA and microRNA, will be addressed in this review. ABSTRACT: Adrenocortical carcinoma (ACC) is a rare cancer with a poor prognosis. Adrenal incidentalomas are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance considering the large differences in clinical behavior requiring different strategies. Diagnosis of ACC starts with a thorough physical examination, biochemical evaluation, and imaging. Computed tomography is the first-level imaging modality in adrenal tumors, with tumor size and Hounsfield units being important features for determining malignancy. New developments include the use of urine metabolomics, also enabling discrimination of ACC from adenomas preoperatively. Postoperatively, the Weiss score is used for diagnosis of ACC, consisting of nine histopathological criteria. Due to known limitations as interobserver variability and lack of accuracy in borderline cases, much effort has been put into new tools to diagnose ACC. Novel developments vary from immunohistochemical markers and pathological scores, to markers at the level of DNA, methylome, chromosome, or microRNA. Molecular studies have provided insights into the most promising and most frequent alterations in ACC. The use of liquid biopsies for diagnosis of ACC is studied, although in a small number of patients, requiring further investigation. In this review, current diagnostic modalities and challenges in ACC will be addressed. MDPI 2021-08-30 /pmc/articles/PMC8431066/ /pubmed/34503194 http://dx.doi.org/10.3390/cancers13174383 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Viëtor, Charlotte L.
Creemers, Sara G.
van Kemenade, Folkert J.
van Ginhoven, Tessa M.
Hofland, Leo J.
Feelders, Richard A.
How to Differentiate Benign from Malignant Adrenocortical Tumors?
title How to Differentiate Benign from Malignant Adrenocortical Tumors?
title_full How to Differentiate Benign from Malignant Adrenocortical Tumors?
title_fullStr How to Differentiate Benign from Malignant Adrenocortical Tumors?
title_full_unstemmed How to Differentiate Benign from Malignant Adrenocortical Tumors?
title_short How to Differentiate Benign from Malignant Adrenocortical Tumors?
title_sort how to differentiate benign from malignant adrenocortical tumors?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431066/
https://www.ncbi.nlm.nih.gov/pubmed/34503194
http://dx.doi.org/10.3390/cancers13174383
work_keys_str_mv AT vietorcharlottel howtodifferentiatebenignfrommalignantadrenocorticaltumors
AT creemerssarag howtodifferentiatebenignfrommalignantadrenocorticaltumors
AT vankemenadefolkertj howtodifferentiatebenignfrommalignantadrenocorticaltumors
AT vanginhoventessam howtodifferentiatebenignfrommalignantadrenocorticaltumors
AT hoflandleoj howtodifferentiatebenignfrommalignantadrenocorticaltumors
AT feeldersricharda howtodifferentiatebenignfrommalignantadrenocorticaltumors